Press release
IgG4-Related Disease Market Size is Projected to grow at a CAGR of 34.60% by 2034, estimates DelveInsight
Download DelveInsight's comprehensive report to explore IgG4-Related Disease market trends, pipeline analysis, and emerging therapies @ [https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the IgG4-Related Disease Market Report
* On January 29, 2026- Sanofi conducted a study is to measure time to IgG4-RD clinical disease flare, and other relevant efficacy endpoints including flare-free rate, control of IgG4-RD disease activity, use of GC rescue and safety parameters such as treatment-emergent adverse events, clinical laboratory values and electrocardiograms (ECG) in participants aged 18 years and above, diagnosed with IgG4-RD and treated with rilzabrutinib tablets over a 52-week placebo-controlled period.
* On January 26, 2026- Acepodia Biotech Inc . announced a ACE1831-201 study is an Open Label, Multicenter, Single Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects with Immunoglobulin G4-Related Disease.
* In 2024, the total diagnosed prevalent cases of IgG4-RD in the United States were approximately 56,800 cases, projected to increase during the forecast period (2025-2034).
* In 2024, gender-specific diagnosed prevalent cases accounted for approximately 39,100 and 17,700 cases for males and females, respectively, in the US.
* The total diagnosed prevalent cases of IgG4-RD in EU4 and the UK were approximately 53,550 in 2024. Males accounted for approximately 38,850 cases, and 14,750 cases in females.
* We have considered six age groups for the categorization of age groups, i.e., 0-17 years, 18-29 years, 30-44 years, 45-64 years, 65-74 years, and =75 years. As per our analysis, a higher percentage of diagnosed prevalent cases was observed in the age group =75 years in Japan. In 2024, the age-specific diagnosed prevalent cases of IgG4-RD in Japan were approximately 12,800 cases in the age group =75 years. The cases will increase during the forecast period (2025-2034).
* The leading IgG4-Related Disease Companies such as Zenas BioPharma, Bristol Myers Squibb, Amgen, Sanofi , and others.
* Promising IgG4-Related Disease Therapies such as Obexelimab (XmAb5871) , and others.
Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ IgG4-Related Disease Treatment Market Size [https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
IgG4-Related Disease Epidemiology Segmentation in the 7MM
* Total diagnosed prevalent cases of IgG4-RD
* Gender-specific diagnosed prevalent cases of IgG4-RD
* Age-specific diagnosed prevalent cases of IgG4-RD
Download the report to understand which factors are driving IgG4-Related Disease epidemiology trends @ IgG4-Related Disease Prevalence [https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
IgG4-Related Disease Marketed Drugs
* UPLIZNA (inebilizumab): Amgen
UPLIZNA is a humanized monoclonal antibody that causes targeted and sustained depletion of key cells that contribute to the underlying disease process (autoantibody-producing CD19+ B cells, including plasmablasts and some plasma cells). After two initial infusions, patients need one dose of UPLIZNA every 6 months. UPLIZNA is also approved for the treatment of Neuromyelitis Optica.
IgG4-Related Disease Emerging Drugs
* Obexelimab (XmAb5871): Zenas BioPharma and Bristol Myers Squibb
Obexelimab (XmAb5871) is a bifunctional monoclonal antibody designed to bind both CD19 and Fc?RIIb, which are broadly present across B-cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. This unique mechanism of action and self-administered SC injection regimen may broadly and effectively address the pathogenic role of B-cell lineage in chronic autoimmune disease. Currently, Zenas is conducting multiple Phase II and Phase III trials of obexelimab in several autoimmune diseases, including IgG4-RD, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. In August 2023, The Lancet Rheumatology published findings from a Phase II study evaluating obexelimab for the treatment of patients with IgG4-RD. Based on these results, a Phase III study in patients with IgG4-RD is ongoing to investigate further the efficacy and safety of obexelimab administered as an SC injection.
Get expert insights and forecasts-download now! @ IgG4-Related Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
IgG4-Related Disease Drugs Market
The current IgG4-RD emerging landscape has only three drugs. Among them, obexelimab (bifunctionally) and UPLIZNA target CD-19. Targeting CD19, a protein found in B cells, shows promise as a treatment for IgG4-RD by depleting B cells, which are thought to play a role in the disease's pathogenesis. Specifically, UPLIZNA, a CD19-targeted antibody, has demonstrated efficacy in reducing flares and achieving remission in IgG4-RD patients.
IgG4-Related Disease Market Outlook
As the etiology of IgG4-RD is unclear and still being studied, no particular medications can cure the disease. For people with IgG4-RD, there are no approved treatments on the market at this time. The criteria for identifying the disease caused by IgG4 levels and patient treatment recommendations were recently detailed in the guidelines released by the "International Consensus Guidance Statement on the Management and Treatment of IgG4-RD."
From market size to emerging drugs, find it all in our latest report. Read now! @ IgG4-Related Disease Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the IgG4-Related Disease Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* IgG4-Related Disease Companies- Zenas BioPharma, Bristol Myers Squibb, Amgen, Sanofi , and others.
* IgG4-Related Disease Therapies- Obexelimab (XmAb5871) , and others.
* IgG4-Related Disease Therapeutic Assessment: IgG4-Related Disease Current marketed and IgG4-Related Disease Emerging Therapies
* IgG4-Related Disease Market Dynamics: IgG4-Related Disease market drivers and IgG4-Related Disease market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* IgG4-Related Disease Unmet Needs, KOL's views, Analyst's views, IgG4-Related Disease Market Access and Reimbursement
Table of Contents
1 Key Insights
2. IgG4-Related Disease Market Report Introduction
3 IgG4-Related Disease Market Overview at a Glance
4 IgG4-Related Disease Epidemiology and Market Forecast Methodology
5 Executive Summary
6 Key Events
7 Disease Background and Overview
8 IgG4-Related Disease Treatment and Management
9 IgG4-Related Disease Epidemiology and Patient Population
10 IgG4-Related Disease Patient Journey
11 IgG4-Related Disease Marketed Therapies
12 IgG4-Related Disease Emerging Therapies
13 IgG4-Related Disease: 7 Major Market Analysis
14 IgG4-Related Disease KOL Views
15 IgG4-Related Disease SWOT Analysis
16 IgG4-Related Disease Unmet Needs
17 IgG4-Related Disease Reimbursement Scenario
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=igg4related-disease-market-size-is-projected-to-grow-at-a-cagr-of-3460-by-2034-estimates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/igg4-related-disease-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release IgG4-Related Disease Market Size is Projected to grow at a CAGR of 34.60% by 2034, estimates DelveInsight here
News-ID: 4369847 • Views: …
More Releases from ABNewswire
Delicate Software Solutions Launches Integrated Mobile Attendance and WPS Payrol …
Image: https://www.abnewswire.com/upload/2026/05/f3b64242a299bb3561ef0466eda58eda.jpg
DUBAI, UAE - Delicate Software Solutions, a premier provider of enterprise automation tools in the Middle East, today announced the official launch of its next-generation Integrated Mobile App Attendance System. This innovative solution is designed to work in seamless tandem with their comprehensive HR and Payroll Software [https://www.delicatesoft.com/hr-payroll-software.html], specifically engineered to simplify Wages Protection System (WPS) compliance and workforce management for small and medium-sized enterprises across the United Arab…
New Report Highlights How Ready Logistics Infrastructure Reduces Operational Del …
In logistics, speed is no longer a competitive advantage - it's an expectation. Businesses expanding into new markets or scaling operations often face the same bottleneck: infrastructure. Construction, approvals, and setting up of facilities can sometimes get in the way of your best laid plans. The growing pressure on organisations to deliver faster has created a new game-changer in logistics and industrial property - the ready-to-use logistics park.
Immediate operational readiness
Ready-to-use…
How Excedify Quietly Redefined GD&T Training and Took the Market with It
Excedify, a relatively new entrant in the GD&T training market, has rapidly gained industry attention by shifting the focus from theoretical instruction to practical application. By introducing a structured 4-level learning pathway and integrating tools like a GD&T symbol generator and a browser-based 2D drawing environment, the company has addressed long-standing gaps in traditional training
For decades, the market for GD&T (Geometric Dimensioning and Tolerancing [https://www.excedify.com/bundles/gdt-certification-pathway]) training followed a predictable pattern.…
Excedify Partners with Michael A. Anleitner to Launch Advanced FMEA Online Train …
Excedify has partnered with Michael A. Anleitner, author of The Power of Deduction: Failure Modes & Effects Analysis for Design (2nd Edition), to develop a modern FMEA online training course. The program is based on the AIAG-VDA 7-step method and focuses on practical application, replacing outdated RPN-only approaches with structured Action Priority (AP) analysis.
Germany - May 4, 2026 - Excedify has announced a strategic partnership with Michael A. Anleitner, author…
More Releases for IgG4
IgG4-Related Disease Market Growing at a CAGR of around 7.4%
IgG4-Related Disease Market
The IgG4-Related Disease (IgG4-RD) market was valued at ~USD 650 million in 2024 and is projected to reach ~USD 1.32 billion by 2034, growing at a CAGR of around 7.4%. Growth is driven by rising diagnosis of autoimmune fibro-inflammatory disorders, increasing specialist awareness, and expanding use of targeted biologics.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71321
Key Market Drivers
• Improved detection through serum IgG4 testing, biopsy, and imaging.
• Rising…
IgG4 - Related diseases Market: Epidemiology, Therapies, Companies, DelveInsight …
The market for IgG4-related diseases is anticipated to grow in the coming years, driven by emerging therapies such as Obexelimab (XmAb5871) and others.
DelveInsight has released a comprehensive report titled "IgG4-Related Diseases - Market Insights, Epidemiology, and Market Forecast 2034", providing an in-depth analysis of IgG4-related diseases, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and…
IgG4-Related Disease Market Set for 34.6% CAGR Growth: Market Drivers and Opport …
DelveInsight's latest market analysis reveals an unprecedented growth trajectory for IgG4-Related Disease therapeutics, featuring breakthrough approvals from Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi targeting multi-organ autoimmune condition.
Key Findings
*
Market size projection: As per DelveInsight's analysis, the total market size of IgG4-Related Disease in the 7MM is expected to reach approximately USD 182 million in 2025, projected to grow at a remarkable CAGR of 34.6% by 2034.
*
Market Drivers: Key market…
IgG4-Related Disease Market to Quadruple, Hitting USD 4 Billion by 2034
IgG4-related disease (IgG4-RD) is a rare, chronic, immune-mediated condition characterized by fibroinflammatory lesions that can affect multiple organs, including the pancreas, salivary glands, kidneys, lungs, and lymph nodes. Often misdiagnosed as cancer or other autoimmune diseases, IgG4-RD has emerged as a significant area of focus in rare disease and immunology research.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71321
Traditionally managed with corticosteroids and immunosuppressants, treatment is evolving with B-cell…
IgG4 - Related diseases Market: Epidemiology, Therapies, Companies, DelveInsight …
IgG4 - Related diseases emerging therapies, such as Obexelimab (XmAb5871), and others, are expected to boost the IgG4 - Related diseases Market in the upcoming years.
DelveInsight has launched a new report on "IgG4 - Related diseases - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the IgG4 - Related diseases, historical and forecasted epidemiology as well as the IgG4 - Related diseases market trends in the…
IgG4-related disease Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trial …
(Albany, USA) DelveInsight's "IgG4-related disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of IgG4-related disease, historical and forecasted epidemiology as well as the IgG4-related disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The IgG4-related disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted IgG4-related disease…
